Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients. Show Notes | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com

Credits

• Written and Produced by: Hannah R. Abrams
  
• Cover Art and Infographic by: Hannah R. Abrams
  
• Hosts: Hannah R Abrams, Matthew Watto MD, FACP
  
• Editor: Clair Morgan of Nodderly.com (audio), Emi Okamoto MD (written)
  
• Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD
  

Sponsor: McGraw Hill

Time Stamps

• 00:00 Sponsor
  
• 00:26 Intro, disclaimer, guest bio
  
• 02:57 Guest one-liner and Picks of the Week*: Michael Pollan audiobook on Coffee and Caffeine Addiction
  
• 03:52 SGLT2i definition, background, and why we now consider CV endpoints in diabetes
  
• 11:16 Sponsor
  
• 12:00 Tubuloglomerular feedback; Balloon analogy
  
• 17:40 Other mechanisms for SGLT2i
  
• 23:05 Back to the case; Risks from SGLT2i; Counseling and Monitoring
  
• 34:18 SGLT2i for non-diabetic kidney disease; Possible mechanisms: Joel’s caution against early adoption
  
• 41:42 SGLT2 inhibitors in kidney transplant
  
• 45:20 Take home points and picks for the SGLT2 inhibitor region
• 49:50 Outro